Dear Editor,

The recent report by Kamel et al. [1] on primary cytomegalovirus infection in pregnant women is very interesting. The authors noted that ‘women who were IgM positive had no primary CMV infection in the index pregnancy as evidenced by the high CMV IgG avidity testing' [1]. In fact, the usefulness of the IgG avidity test was previously reported by Seo et al. [2], who noted that this test ‘enabled the identification of women who were at a low risk of transmitting CMV infection and provided informative for subsequent pregnancy outcomes'. However, the diagnostic property of the IgG avidity test should be mentioned. The sensitivity of this test was reported to be only 85.7% [3]. Lumley et al. [4] also recently reported that ‘women with positive IgM and low avidity IgG' might not present a primary CMV infection.

1.
Kamel N, Metwally L, Gomaa N, et al: Primary cytomegalovirus infection in pregnant Egyptian women confirmed by cytomegalovirus IgG avidity testing. Med Princ Pract 2014;23:29-33.
2.
Seo S, Cho Y, Park J: Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidity test. Korean J Lab Med 2009;29:557-562.
3.
Lafarga B, Noguera FJ, Bolanos M, et al: Performance of the IgG avidity test in patients with cytomegalovirus disease (in Spanish). Enferm Infecc Microbiol Clin 1997;15:190-195.
4.
Lumley S, Patel M, Griffiths PD: The combination of specific IgM antibodies and IgG antibodies of low avidity does not always indicate primary infection with cytomegalovirus. J Med Virol 2014;86:834-837.

ReplyN. Kamela, L. Metwallyb, N. Gomaab, W.A. Sayed Ahmedc, M. Lotfic, S. YounisaDepartments of aClinical Pathology, bMicrobiology and cObstetrics and Gynecology, Faculty of Medicine, Suez Canal University, Ismailia, EgyptDear Editor,We would like to thank Prof. Viroj Wiwanitkit for his interest in our study [1]. Lazzarotto et al. [2] stated that: ‘If determination of the anti-CMV antibody avidity is carried out early (before 18 weeks), it can identify all pregnant women who will transmit congenital CMV infection to their offspring. Moreover, if determination of avidity index is carried out later on during pregnancy, 60% of women who will transmit the infection still have antibody with low avidity, while the others will develop moderate or high avidity.'We could not find the English version of the relatively old report from Lafarga et al. [3], and the method used for the IgG avidity analysis was not clarified. In recent years, many new fully automated assays with high sensitivities and specificities have been developed by different manufacturers; for example, Abbott uses a chemiluminescent microparticle immunoassay (CMIA) performed on the ARCHITECT [4], BioMérieux uses an enzyme-linked fluorescent assay (ELFA) performed on the VIDAS, and DiaSorin uses a chemiluminescence immunoassay (CLIA) performed on the LIAISON analyzer. In our study, we used the VIDAS CMV-IgG avidity assay. In a recent report by Vauloup-Fellous et al. [5], they suggested ‘new VIDAS cut-off values of 0.40 for low avidity and 0.65 for high avidity, which significantly increase the test performance and enable better patient managements'. Also, they ‘demonstrated that the VIDAS CMV-IgG avidity assay allows observing correctly the maturation of CMV-IgG avidity, which could be useful as an additional parameter for diagnosis of a recent CMV infection'.Lumley et al. [6] recently reported that pregnant women with positive IgM and low/equivocal avidity testing on the Abbott ARCHITECT and DiaSorin LIAISON assays persisted over 18 weeks and therefore they may not have had primary infections. They suggested that a larger series of patients should be examined to determine how frequently this phenomenon occurs.References 1 Kamel N, Metwally L, Gomma N, et al: Primary cytomegalovirus infection in pregnant Egyptian women confirmed by cytomegalovirus IgG avidity testing. Med Princ Pract 2014;23:29-33. 2 Lazzarotto T, Spezzacatena P, Varani S, et al: Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin Diagn Lab Immunol 1999;6:127-129. 3 Lafarga B, Noguera FJ, Bolanos M, et al: Performance of the IgG avidity test in patients with cytomegalovirus disease (in Spanish). Enferm Infecc Microbiol Clin 1997;15:190-195. 4 Lagrou K, Bodeus M, Van Ranst M, et al: Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J Clin Microbiol 2009;47:1695-1699. 5 Vauloup-Fellous C, Berth M, Heskia F, et al: Re-evaluation of the VIDAS® cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG maturation. J Clin Virol 2013;56:118-123. 6 Lumley S, Patel M, Griffiths PD: The combination of specific IgM antibodies and IgG antibodies of low avidity does not always indicate primary infection with cytomegalovirus. J Med Virol 2014, DOI: 10.1002/jmv.23863.Noha Kamel, MDDepartment of Clinical Pathology, Faculty of MedicineSuez Canal UniversityIsmailia (Egypt)E-Mail nkamel30@yahoo.com

Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.